Abstract:The results of clinical trials conducted in Europe and North America have been incorporated into treatment strategies for breast cancer in Japan. Despite the use of similar treatment regimens, why has mortality from breast cancer been increasing in Japan? Procedures for surgical treatment and sentinel lymph node biopsy in breast cancer do not differ between Japan and Western countries, but the strategies for radiotherapy differ slightly. Hormonal therapy is now selected on the basis of scientific evidence, and similar regimens are used in Japan and Western countries. As for postoperative adjuvant chemotherapy, an anthracycline plus cyclophosphamide and taxane-based regimens are standard treatments in Japan and Western countries. In 2009, however, the results of two large clinical studies designed to determine whether intravenous or oral treatment was superior for postoperative adjuvant chemotherapy were reported in Japan. Both studies showed that relapse-free survival and overall survival (OS) at 5 years after surgery were similar for a combination of cyclophosphamide, methotrexate, and 5-fluorouracil and for tegafur/uracil. Many chemotherapeutic agents that are used to treat recurrent or metastatic breast cancer have not yet been approved in Japan. As for molecular targeted therapy, some agents that target the human epidermal growth factor receptor family have been approved in Japan, whereas angiogenesis inhibitors have not. The results of many clinical trials have been incorporated into clinical practice in Japan, therefore, the outcomes of breast cancer therapy have surpassed those in other countries. Many pivotal clinical trials have been conducted outside Japan. Treatment regimens that have been developed on the basis of these studies might be suitable for the management of breast cancer in Western women, but not for Japanese women because of differences in genetic factors, physique, body mass index, pharmacokinetics, and drug metabolism. Such regimens should be modified on the basis of the characteristics of breast cancer in Japan to develop treatment that is optimally suited for Japanese women. In particular, local studies of pharmacokinetics, pharmacodynamics, and optimal dose levels and treatment intervals should be carefully performed. The establishment of treatment regimens optimally suited for Japanese patients with breast cancer could put the brakes on the trend towards increasing mortality from breast cancer in Japan.

Current status of head and neck sarcomas in Japan in 2016–2019: an analysis using the national cancer registry

Clear cell sarcoma in Japan: an analysis of the population-based cancer registry in Japan

Statistics of bone sarcoma in Japan: report from the population-based cancer registry in Japan

Statistics of Visceral Sarcoma in Japan: Report From the Population-Based National Cancer Registry (NCR) in Japan

Subsite-specific trends in mid- and long-term survival for head and neck cancer patients in Japan: A population-based study

Definitive radiotherapy for nasopharyngeal carcinoma in Japan: analysis of cases in the National Head and Neck Cancer Registry from 2011 to 2014

Adult genitourinary sarcoma: analysis using hospital-based cancer registry data in Japan

Mucosal melanoma of the head and neck: a retrospective analysis of 34 cases in Japan

Research progress in diagnosis and treatment of synovial sarcoma of the head and neck

Global frequency and distribution of head and neck sarcomas in adulthood: a systematic review

Retroperitoneal sarcoma: a 10-year follow-up analysis using hospital-based cancer registry data in Japan

Maediastinal germ cell tumors: analysis using hospital-based cancer registry data in Japan

Efficacy of Neoadjuvant Chemotherapy for Synovial Sarcoma: Retrospective Analysis of a Nationwide Database in Japan

Current status of therapy for breast cancer worldwide and in Japan

Comprehensive registry of esophageal cancer in Japan, 2013

Surgically treated gastric cancer in Japan: 2011 annual report of the national clinical database gastric cancer registry

Mutational landscape of Japanese patients with oral squamous cell carcinoma from comprehensive genomic profiling tests

Surgically resected sarcomatoid carcinoma of the lung: a nationwide retrospective study in 2010

Epidemiological and therapeutic profiles of lung cancer patients in the Hokushin Region Japan: a retrospective hospital administrative database study

Clinical epidemiology of the endoscopic, laparoscopic, and surgical resection of malignant gastric tumors in Japan, 2014–2021: a retrospective study using open data from a national claims database

Clinical outcomes and prognostic factors of concurrent chemoradiotherapy for anal squamous cell carcinoma in Japan